Amneal to Report First Quarter 2021 Results on May 7, 2021

Rhea-AI Summary

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2021 financial results on May 7, 2021, before market open. A conference call will be held at 8:30 a.m. Eastern Time on the same day, accessible via the Investor Relations section of their website. Access the call at (844) 746-0741 for U.S. callers or (412) 317-5273 internationally. A replay will be available for seven days after the call. Amneal focuses on the development and distribution of generic and specialty pharmaceuticals, with significant operations in North America, Asia, and Europe.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 7, 2021.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

To access the call through a conference line, dial (844) 746-0741 (in the U.S.) or (412) 317-5273 (international callers).

A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial (877) 344-7529 (in the U.S.) or (412) 317-0088 (international callers). The access code for the replay is 10154969.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

The Company also owns 65% of AvKARE. AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. For more information, visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005023/en/

FAQ

When will Amneal Pharmaceuticals release its Q1 2021 financial results?

Amneal Pharmaceuticals will release its Q1 2021 financial results on May 7, 2021, before market open.

What time is the conference call for Amneal Pharmaceuticals Q1 2021 results?

The conference call is scheduled for 8:30 a.m. Eastern Time on May 7, 2021.

How can I access the Amneal Pharmaceuticals Q1 2021 conference call?

You can access the call by dialing (844) 746-0741 for U.S. callers or (412) 317-5273 for international callers.

Is there a replay available for the Amneal Pharmaceuticals conference call?

Yes, a replay of the conference call will be available for seven days after the call, accessible at (877) 344-7529 in the U.S. or (412) 317-0088 internationally.

Where can I find more information about Amneal Pharmaceuticals?

More information can be found on Amneal's website at www.amneal.com.